Condition: Metastatic Urothelial Cancer · Sponsor: Gilead Sciences
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
This description comes directly from the study's public registry record.
Gilead Clinical Study Information Center · 1-833-445-3230 (GILEAD-0) · GileadClinicalTrials@gilead.com
Always discuss trial participation with your own doctor first.
| The University of Arizona Cancer Center-North Campus | Tucson, Arizona, United States | Recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | Withdrawn |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Littleton, Colorado, United States | Recruiting |
| Smilow Cancer Hospital at Yale-New Haven | New Haven, Connecticut, United States | Recruiting |
| Eastern Connecticut Hematology and Oncology Associates | Norwich, Connecticut, United States | Withdrawn |
| Mount Sinai Comprehensive Cancer Center | Miami Beach, Florida, United States | Recruiting |
| Woodlands Medical Specialists, PA | Pensacola, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | Completed |
| University of Illinois Cancer Center | Chicago, Illinois, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
+ 123 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03547973